Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase Ib Escalating Dose, Open-Label, Signal-Finding Study to Evaluate the Safety, Tolerability, and Short-Term Efficacy of the Anti-Light Monoclonal Antibody MDGN-002 in Adults With Moderate to Severe Active Crohn's Disease or Ulcerative Colitis Who Previously Failed Treatment With an Anti-TNFα Agent

NCT03169894 is registered in ClinicalTrials.gov with Avalo Therapeutics, Inc. as lead sponsor.

NCT NCT03169894
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03169894 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase Ib Escalating Dose, Open-Label, Signal-Finding Study to Evaluate the Safety, Tolerability, and Short-Term Efficacy of the Anti-Light Monoclonal Antibody MDGN-002 in Adults With Moderate to Severe Active Crohn's Disease or Ulcerative Colitis Who Previously Failed Treatment With an Anti-TNFα Agent
Lead sponsor
Avalo Therapeutics, Inc.
Phase
Phase 1
Overall status
Terminated
Start date
July 14, 2017
Completion date
October 12, 2021
Enrollment
8 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

crohn disease, ulcerative colitis